Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Depakote ER in Borderline Personality Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00222482
Recruitment Status : Completed
First Posted : September 22, 2005
Last Update Posted : August 9, 2007
Sponsor:
Collaborators:
Abbott
Schulz, S. Charles, M.D.
Information provided by:
University of Minnesota

Brief Summary:
This study examines the effect of Depakote ER versus placebo in a randomized trial of borderline personality disorder. Patients all participate in DBT therapy and those who are not responsive are assigned to either Depakote ER or placebo for up to 12 weeks. Borderline Personality Symtoms are measured and side-effects are assessed.

Condition or disease Intervention/treatment Phase
Borderline Personality Disorder Drug: Depakote ER Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Double-Blind and Placebo Controlled Assessment of Depakote ER in Borderline Personality Disorder
Study Start Date : March 2003
Actual Study Completion Date : September 2005

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Symptom Checklist 90

Secondary Outcome Measures :
  1. Barratt Impulsivity Scale


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   21 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:Male or female patients with the diagnosis of borderline personality disorder between the ages of 21 adn 55 years old. Must be in good physical health -

Exclusion Criteria:Major psychiatric illness on Axis I - schizophrenia or bipolar disorder. May not have current MDD. May not be dependent on illicit substances or alcohol.

-


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00222482


Sponsors and Collaborators
University of Minnesota
Abbott
Schulz, S. Charles, M.D.
Investigators
Layout table for investigator information
Principal Investigator: Sellamnn C Schulz, M.D. Department of Psychiatry, University of Minnesota Medical School
Publications:
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00222482    
Other Study ID Numbers: 0306M49703
M009946
First Posted: September 22, 2005    Key Record Dates
Last Update Posted: August 9, 2007
Last Verified: August 2007
Keywords provided by University of Minnesota:
Borderline Personality Disorder
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Personality Disorders
Borderline Personality Disorder
Pathologic Processes
Mental Disorders
Valproic Acid
Anticonvulsants
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
GABA Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Antimanic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs